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Nitric oxide (NO) may exhibit proinflammatory features. *NO synthase type 2 (NOS2) is
overexpressed and 'NO overproduced in rodent models of induced inflammation. Blockage of
'NO production by administration of NOS inhibitors prevents or reduces various types of induced
inflammation in mice and rats. We have shown that autoimmune MRL-lpr/1pr mice overexpress
NOS2 and overproduce 'NO in an age-dependent fashion that parallels expression of arthritis,
glomerulonephritis, and vasculitis. Blocking 'NO production by oral administration of the NOS
inhibitor M\-monomethyl-L-arginine reduced the arthritis, glomerulonephritis, and vasculitis, but it
did not modify serum anti-DNA antibody levels or glomerular deposition of immune complexes.
When mice with genetically disrupted NOS2 were backcrossed to MRL-lpr/1pr mice, the resultant
(-/-) mice expressed no NOS2 and produced no 'NO, the wild-type (+/+) mice overexpressed
NOS2 and overproduced 'NO (in comparison to normal, control mice), and the heterozygous (+/-)
mice expressed and produced intermediate levels. Nephritis and arthritis in the (-/-) mice were
comparable to that in MRL-lpr/lpr mice, but vasculitis was markedly decreased. Levels of anti-
DNA antibodies were comparable in all mice, but lgG rheumatoid factor production was markedly
reduced in the (-/-) mice. These results of studies in MRL-lpr/lpr mice with genetically disrupted
NOS2 highlight the heterogeneity and complexity of the role of NOS2 and 'NO in inflammation.
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Overview
Inflammatory joint tissue in rheumatoid
arthritis (RA) is characterized by infiltration
and accumulation ofmononuclear phago-
cytes, lymphocytes, and plasma cells, pro-
liferation ofsynovial cells, and expression
of proinflammatory cytokines (1-3).
Although some cytokines are undetectable
or are present in only low levels in rheuma-
toid synovia, synovial macrophages and
fibroblasts in this disease are a good source
of cytokines such as interferon (IFN)-a,
interleukin (IL)-1, tumor necrosis factor
(TNF)-a, IL-6, IL-8, and granulocyte
macrophage-colony-stimulating factor
(4-7). In addition to these protein media-
tors, arachidonic acid metabolites, reactive
oxygen species ([ROS], superoxide anion
radical 02-, hydrogen peroxide, and
hydroxyl radical), and reactive nitrogen
species (nitric oxide ['NO], and related
molecules such as peroxynitrite [OONO-])
likely contribute to the pathology. The
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combined actions of these mediators
(along with certain inherent and induced
anti-inflammatory mediators) contribute
to the eventual pathology-accumulation
ofinflammatory cells, modification ofsyn-
ovial vascular cells, proliferation of syn-
ovial fibroblasts, disruption of the general
synovial architecture, and destruction of
cartilage and bone. NO, 02,- and
OONO- appear to be central to the
inflammatory process. Antioxidant
enzymes such as catalase, superoxide dis-
mutase (SOD), and glutathione peroxidase
may be critical as endogenous defenses
against inflammation. Various cells in the
joint may participate in the inflammation.
These include mononuclear phagocytes
and chondrocytes.
NO and Nitric Oxide
Synthase
The simple gas NO has multiple important
physiologic and pathologic functions
[(8-10) for reviews]. These include roles in
(to mention only a few) host resistance to
tumors and microbes, regulation ofblood
pressure and vascular tone, neuro-
transmission, learning, and neurotoxicity,
carcinogenesis, and control of cellular
growth and differentiation (11,12). In the
presence ofoxygen, NO rapidly (seconds)
is converted to nitrite and nitrate, sub-
stances that are generally not bioactive
[(13) for review]. NO binds with high
affinity to iron in heme groups ofproteins
such as hemoglobin (Hb), myoglobin
(Mb), and guanylyl cyclase; Hb and Mb
are very effective quenchers of*NO action.
NO also reacts with 02-- and SOD pro-
longs NO life by eliminating 02---. On
reacting with 02'-, 'NO may form
OONO-, a very toxic/reactive molecule
that may be the most important effector
toxic molecule when one thinks of 'NO
toxicity in oxygenated systems.
There are three forms of the enzyme
nitric oxide synthase (NOS) encoded by
three different genes. Neural NOS (nNOS
or NOSI) and endothelial cell NOS
(eNOS or NOS3) are constitutive
enzymes, demonstrating low-level, con-
stant transcription of mRNA. The enzy-
matic actions of NOS1 and NOS3 are
modulated by regulation of cytoplasmic
calcium levels, with agents inducing
increases in calcium (e.g., calcium
ionophores, ligands such as acetylcholine,
or mechanical stress), with subsequent
binding to calmodulin and activation of
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the enzyme. Inducible NOS (iNOS or
NOS2) can be regulated at multiple levels,
but induction ofmRNA transcription by
agents such as cytokines or lipopolysaccha-
ride (LPS) appears to be ofmajor impor-
tance [(14) for review]. The activity of
NOS2 is generally thought to be calcium
independent. Although NOS2 was
described initially in mononuclear phago-
cytes, it also is found in synoviocytes, chon-
drocytes, smooth musde cells, hepatocytes,
and others (8,9,15-17).
Regulation of NOS2 can occur at
multiple steps (14), including mRNA
transcription, stability, and translation. At
the protein level, NOS may be regulated
by calmodulin binding, dimer formation
(the functional enzyme exists as a dimer),
substrate (L-arginine) depletion, substrate
recycling (L-citrulline to L-arginine),
tetrahydrobiopterin availability, end prod-
uct inhibition ('NO interaction with
NOS heme), phosphorylation, and sub-
cellular localization. Important NOS
cofactors include FAD, FMN, NADPH,
tetrahydrobiopterin, and calmodulin-cal-
cium. For NOS2, calmodulin is tightly
bound to protein, making it relatively
resistant to inhibition by calcium chela-
tors. Activities ofNOS can be influenced
by tetrahydrobiopterin levels, and
cytokines/LPS can enhance tetrahydrobio-
pterin production (18,19). Heme is a crit-
ical component ofNOS; 'NO can act as a
feedback inhibitor of NOS activity by
binding to the iron in heme (20,21).
Human Mononuclear
Phagocyte NOS2 Expression
and NO Production
Several researchers have shown high-level
*NO production by murine macrophages,
but many have difficulty showing that
human monocytes or macrophages pro-
duce *NO in vitro [(22) for review].
Because of this, some investigators have
questioned the roles of mononuclear
phagocyte NOS2 and 'NO in human dis-
ease. However, human hepatocytes,
chondrocytes, and human DLD-1 colon
tumor cells can express NOS2 mRNA and
produce high levels of'NO after treatment
with cytokines and LPS (15,16,23-25).
Some have shown human monocyte 'NO
production, but levels have been low when
compared to murine mononuclear phago-
cytes [(22,26-28) for review]. In a study of
normal human monocytes and peritoneal
macrophages, we showed that these cells
can produce NOS2 mRNA, protein, and
'NO, but levels were much less than that
ofmouse macrophages (29). We examined
a large array of culture conditions and
cytokines. IFN-y and LPS showed only
slight activity. Human alveolar macro-
phages have NOS2 antigen (30,31), and
patients with tuberculosis have increased
numbers of alveolar macrophages that
express NOS2 antigen (32). Humans can
be induced to make high levels of *NO in
vivo via an NOS mechanism (33), but the
cells responsible for *NO production in
vivo are not known. We have recently
noted that children with mild malaria
overproduce 'NO and have mononuclear
cells that express NOS2 antigen (34). We
have also noted that RA patients have
overexpression ofNOS2 antigen in blood
mononuclear cells, and that their mono-
cytes have enhanced *NO production in
vitroand enhanced responsiveness to treat-
ment with IFN-y and LPS (35). Thus,
human mononuclear phagocytes can
express NOS2 and generate 'NO, and
human NOS2 expression and *NO gener-
ation correlate with the severity ofcertain
diseases, including the autoimmune
disease RA.
NO and Inflammation
'NO has many actions appropriate for a
proinflammatory agent. It is made by
numerous cell types in sites ofinflamma-
tion, and it increases blood flow and vascu-
lar permeability. *NO has cell/tissue
destructive abilities, and it can induce cyclo-
oxygenase (COX), cause pain, destroy cer-
tain protease inhibitors, and enhance
production ofIL-1 and TNF, and NADPH
oxidase activity in myeloid cells (11,36).
'NO production may result from the
actions ofseveral substances including cyto-
kines, immune complexes, and bacterial
products (Figure 1). Because 02-- may
interact with 'NO to produce OONO-,
coincident production of'NO and O2f-sets
the stage for a severe inflammatory state.
In the joint, several cell types may pro-
duce 'NO-macrophages, chondrocytes,
endothelial cells, and possibly others.
Macrophages and chondrocytes are the
most likely contributors. Human articular
chondrocytes produce relatively high levels
of 'NO, and cytokines can augment this
production (15,37,38). Synovial fibroblasts
in patients with arthritis also express
NOS2 and produce 'NO (39). Because
several paths might lead to increased 'NO
production, blocking only one pathway
(e.g., blocking an IFN alone) might not
fully blunt 'NO production, since alternate
paths could compensate (Figure 1).
Researchers have noted that in addition
to proinflammatory effects, 'NO may also
be anti-inflammatory. The double-edged
sword phenomenon in *NO biology thus
applies to inflammation as well as to
other areas in *NO biology (8,40). *NO
modifies adhesiveness and chemotaxis of
polymorphonuclear neutrophils and
monocytes (41,42), inhibits platelet aggre-
gation and secretion (43), and inhibits cell
proliferation [including lymphocytes (8)].
Arachidonic acid metabolites play
important roles in inflammation, and COX
inhibitors are drugs useful in the manage-
ment of inflammatory disease (44). There
is significant cross-talk between *NO and
COX. Eicosanoids can reduce NOS2
expression and 'NO production (45-47),
and *NO modulates prostaglandin E2
formation (48). Stimuli that enhance
NOS2 and *NO formation also may
induce COX2 expression, but the time
course for induction differs (49-51).
Arginine analogues such as NG_
monomethyl-L-arginine (NMMA) may be
anti-inflammatory by inhibiting both
COX2 and NOS (52). Furthermore,
aspirin, in high doses, inhibits both
cyclooxygenase andNOS2 (53).
'NO is important in animal models of
arthritis that mimic human RA. These
include adjuvant arthritis, collagen-
induced arthritis, and spontaneous arthritis
in MRL mice [(36,38,54) for reviews].
Likewise, 'NO participates in the
Microbial Immune Other Cytokines products complexes activators
Cellular NOS2activation]
X -NOS inhibition
02- NO
X -'NO quenching
(OONO-,'OH, and etc.)
Inflammation
Figure 1. Nitric oxide and inflammation. Cellular NOS2
can be activated by a variety of cytokines (e.g., IFN-y,
TNF), microbial products (e.g., endotoxin), immune
complexes, and others. The formed 'NO can by itself,
orthrough interaction with superoxide and other more
reactive molecules, initiate and propagate inflamma-
tion. NOS2 can be inhibited by various means (e.g.,
i-arginine antagonists, tetrahydrobiopterin depletion,
L-arginine depletion). 'NO effects can be quenched by
molecules (e.g., hemoglobin, hydroxocobalamin).
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pathogenesis of spontaneous myositis in
the SJL mouse (55). Mice with genet-
ically disrupted transforming growth fac-
tor P1 (TGF-P) have severe multifocal
inflammation, and they die after only 2 to
3 weeks oflife. These mice have overex-
pression of NOS2 and overproduction of
'NO (56). The overproduction of NO is
inhibited by treatment with NMMA in
vivo. The absence ofTGF-,B, an inhibitor
of NOS2 transcription and translation
(57), appears to cause a systemic lethal
inflammatory condition that results from
'NO overproduction.
'NO may be increased in synovial fluid
and serum of patients with RA (58-60).
Kaur and Halliwell (61) showed increased
levels ofnitrotyrosine (a product resulting
from OONO- action) in serum and syn-
ovial fluid from arthritis patients (61).
Sakurai et al. (62) found that synovia from
patients with RA and osteoarthritis (OA)
produce 'NO in vitro, and express NOS2
mRNA (reverse transcriptase-polymerase
chain reaction) and protein (immunoblot
and immunohistology). The NOS2 was
associated primarily with CD14+ cells
(mononuclear phagocytes). Other investiga-
tors have also found that synovial fibroblasts
(as well as macrophages) from patients with
RA and OA produced 'NO and expressed
NOS2 (39). Ueki and co-workers (63)
showed that RA patients have higher serum
'NO than do osteoarthritis (OA) patients,
that RA synovial fluid 'NO was much
higher than serum 'NO, and that serum
*NO levels correlated significantly with clin-
ical parameters ofdisease activity (duration
ofmorning stiffness, number ofswollen and
tender joints, and serum levels ofC-reactive
protein, TNF, and IL-6). We had earlier
noted comparable associations (35).
The MRL-Ipr/lIprModel of
Autoimmunity
These mice develop a disease that resembles
human systemic lupus erythematosus and
RA (64). They have autoantibodies,
rheumatoid factor, arthritis, nephritis, and
vasculitis, and they die prematurely from
disease. They have lymphadenopathy and
splenomegaly, and a defect in apoptosis
caused by a mutatedfas gene (an insert of
the early transposable element resulting in
aberrant splicing and premature termina-
tion oftranscription) (65). Fas protein is a
membrane protein that, after ligation with
an antibody or with its ligand FasL, causes
cell death by apoptosis. C3H-gld mice are
similar to MRL-/pr/lpr mice in that they
have generalized lymphadenopathy and a
defect in apoptosis. The gld defect is a
defect in the fasL gene, that encodes the
ligand for Fas. Mice of both strains have
increased numbers of CD4-, CD8-, and
CD3+ cells. These cells are polyclonal and
nonmalignant. Fas is essential for the acti-
vation-induced death of mature T cells in
the periphery but not in the thymus. In
MRL-lpr/lpr mice, failure of apoptosis
results in persistence ofautoreactive T cells
that help autoreactive B cells that are not
eliminated. Genetic factors in addition to
lpr are also important in determination of
disease. MRL mice without thefas abnor-
mality still develop an autoimmune disor-
der (albeit less severe). Our work showed
while enhanced NOS2 expression and
'NO production are critical for disease
development, disease likely does not result
from an abnormality in the NOS2gene per
se (66). Because these mice have high
serum and tissue levels of immune com-
plexes and various cytokines (including
IFN-y, IL-12, and TNF), activation may
result from these factors. We and others
have proposed potential final effectors of
disease; these include arachidonic acid
metabolites, ROS, and 'NO (66-68).
Humans withfasgene mutations, defective
apoptosis, and autoimmune abnormalities
have been recently described (69,70).
NO, OONO-, Inflammation,
and Arthritis
We noted earlier that the macrophages of
MRL-/pr/lpr mice are activated in various
ways, including enhanced ROS generation
(67). We hypothesized that they might
also overproduce 'NO (66), and we
demonstrated that they spontaneously
excrete 5 to 10 times more urinary
nitrite/nitrate (stable oxidation products of
*NO) than normal mice. They have
enhanced expression ofNOS2 mRNA and
protein in macrophages, liver, kidney, and
spleen. NOS2 maps to mouse chromosome
1 1 (corresponding to human 17p21); this
location is different from sites previously
determined to be linked to disease suscepti-
bility [chromosome 19 (fas), 7 and 12],
making it unlikely that a defect in the
NOS2 gene is the cause of this autoim-
mune disorder. Treatment of the mice
with NMMA orally blocks the 'NO over-
production, and it prevents or blunts the
development of arthritis, nephritis, and
vasculitis, indicating that 'NO is causally
related to the disease. Despite marked im-
provement in renal function and histology,
drug treatment does not reduce the serum
levels of anti-DNA antibody or alter
deposition of immune complexes. Other
workers have corroborated our findings of
overproduction of NO in these MRL-
lpr/Ipr mice and extended the findings to
another strain of mice with autoimmune
disease (i.e., New Zealand white/New
Zealand black) (71,72).
'NO binds to Hb tightly to form
nitrosylhemoglobin (NOHb). This NOHb
can be accurately detected by electron
paramagnetic resonance techniques
(EPR). Nonhuman animals in septic
shock and humans receiving intravenous
nitroglycerin have detectable levels of
NOHb (73). We measured NOHb in
whole blood. MRL-lpr/lpr mice had statis-
tically significant elevated levels ofNOHb
in blood (74). This increased with age
and paralleled the course of 'NO overpro-
duction. We also examined the kidneys
using EPR and found that MRL kidneys
have a nitrosyl nonheme iron protein sig-
nal, as well as some NOHb (probably
from blood trapped in the kidney). The
nitrosyl nonheme iron protein at g= 2.04
may be an iron-sulfur cluster protein such
as one of the mitochondrial electron
transport enzymes.
Our studies showed that kidneys from
MRL mice have an increase in the amount
of nitrotyrosine-containing proteins.
Nitrotyrosine is formed as a consequence
of action of OONO- on tyrosine in pro-
teins, and thus may serve as a marker of
'NO and OONO- action in tissues
(75-77). On immunoblots using specific
antinitrotyrosine antibody, extracts from
kidneys from normal mice were essentially
negative, whereas those from MRL mice
had two major bands of immunoreactivity
(A,= 60,000 and 48,000) and three minor
bands (78). Reactivity was eliminated by
omitting the primary antibody or by co-
incubating the primary antibody reaction
mixture with 10 mM nitrotyrosine. The
identity of the nitrated proteins in the tis-
sues from the diseased kidneys is presently
unknown. 'NO and OONO- can react
with numerous different proteins, and
these reactions can alter functions ofsome
(9,10). In an attempt to identify one ofthe
target proteins for 'NO and OONO-, we
measured catalase activity in the mouse
kidneys. Catalase levels were diminished in
MRL mice, and this decrease was pre-
vented by treating them with NMMA in
vivo. In in vitro studies, we noted that
OONO-would inactivate purified catalase.
This suggested that catalase is one of the
target proteins inactivated by 'NO and/or
OONO-. All this indicates that catalase
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can serve as a target for OONO--mediated
modification, and that the modified protein
has decreased activity. Thus, in the MRL
mice, there is overproduction ofoxidants
(NO, 02-, and OONO-) with depletion
of the antioxidant enzyme catalase. This
produces the setting of extreme oxidant
stress. Evidence ofincreased lipid peroxida-
tion and oxidant stress in these mice has
been reported (79).
Targeted Disruption ofthe
Genesfor NOS2
Studies using homologous recombination
between incoming DNA and a chosen
target gene (gene targeting) in embryonic
stem cells to make planned changes in the
mouse germ line have allowed production
ofdesired knockout (KO) mice. One can
study the effects ofthe absence ofgenes
and their products. KO models for the
three isoforms of NOS [NOS1 (80),
NOS2 (81-83), and NOS3 (84)] have
been reported. Mice ofeach ofthese KOs
develop normally, reproduce, and appear
grossly normal. The NOS1 KO mice have
gastromegaly due to absence of *NO-
releasing neurons in the pylorus of the
stomach, and they are overly aggressive.
NOS3 KO mice have hypertension (84).
NOS2 KO mice do not elevate levels of
*NO after immune stimulation or after
LPS injection, and their macrophages can-
not make NOS2 protein or 'NO (81,83).
They have enhanced susceptibility to dis-
seminated infection with Leishmania and
Listeria monocytogenes, and anesthetized
mice may have increased lethality after
challenge with high doses of LPS (espe-
cially those mice who have previously been
injected with Corynebacterium parvum).
One group has shown that awake,
untreated NOS2 KO mice are not resistant
to LPS-induced death (82), suggesting that
other factors are operative in this complex
model of shock. NOS2 KO mice have
diminished paw swelling after injection of
carrageenin, and their lymphocytes show
increased production of Th2 cytokines
after stimulation in vitro (83). NOS2 KO
mice have reduced resistance to infection
with Leishmania major and Mycobacteria
tuberculosis (83,85).
NOS2 Knockout Mouse
Studies in Autoimmune Mice
We have crossed the NOS2 KO mice
with MRL mice, and these are to four
backcrosses (N4). Because the embryonic
stem cells are the 129 strain, the targeted
mice are not genetically homogeneous,
but N4 mice have diluted out most of
129 strain ofthe embryonic stem cells and
express essentially the MRL background.
MRL-lpr/lpr littermates homozygous for
disrupted NOS2 [(-I-)], heterozygous for
disrupted NOS2 [(+1-)], or no disruption
of NOS2 [(+/+)] were derived for this
study (86).
The (+/+) mice excreted large amounts
of nitrite/nitrate, confirming our prior
observations (66). The (+/-) mice excreted
intermediate levels, whereas (-/-) mice
excreted very low levels ofnitrite/nitrate
(comparable to those ofnormal BALB/c
mice). Nitrite/nitrate levels in sera from
20-week-old animals paralleled the urinary
measures, with very low levels in the (-/-)
mice, high levels in the (+/+) mice, and
intermediate levels in the (+/-) mice.
Levels ofurinary and serum nitrite/nitrate
in (+/+) or (+/-) mice were significantly
higher than those in the (-/-) mice (86).
To assess in vitro 'NO production by
cells from mice ofthe three groups, we cul-
tured peritoneal macrophages without
additives and with IFN-,y (50 U/ml) and
LPS (10 ng/ml). Nitrite/nitrate levels were
significantly lower in the tissue culture
supernatants of macrophages from the
(-/-) mice than (+/+) mice or the (+/-)
mice, both at baseline and following stimu-
lation. Similarly, NOS2 enzyme activity, as
measured by the conversion ofL-arginine
to L-citrulline, was significantly less in the
cells from (-/-) mice than those from (+/-)
or (+/+) mice. NOS activities were reduced
by more than 90% by inclusion of2 mM
NMMA in the reaction mixtures. These
studies confirm lack of detectable NOS
activity in (-/-) mice (86).
Immunoblots were performed on
protein extracts from spleens, kidneys,
liver, and peritoneal macrophages from the
mice using an anti-NOS2 antibody. The
macrophage cell lineJ774 (no treatment or
treated with LPS/IFN-y) served as control.
As noted earlier, tissue from BALB/c mice
had no NOS2. There was minimal or no
detectable NOS2 in the splenic, kidney
and macrophage protein extracts from
(-/-) mice. Extracts from (+/+)and (+/-)
mice contained NOS2 protein, with those
of the (+/-) mice having approximately
halfthe amount ofthe (+/+) mice (86).
Based on the effect of in vivo
administration ofNMMA on renal disease
and arthritis in MRL-Ipr/ipr mice (66), we
predicted that (-/-) mice would develop
less renal disease and arthritis than mice of
the other two groups. Twenty-four-hour
urinary protein excretion at 20 weeks of
age was less in the (-/-) mice than in the
other two groups (but not statistically
significantly different), suggesting a possi-
ble difference in renal disease. Pathologic
examination, however, indicated that glo-
merulonephritis in the (-/-) mice was sim-
ilar in severity to that of the other two
groups. Proliferative glomerulonephritis
was present in all mice regardless ofNOS2
genotype, with overall glomerular scores
similar between the groups. Crescentic glo-
merulonephritis and interstitial disease was
present in a small number ofmice in each
group. Synovitis was present in most ofthe
mice, with overall synovial scores similar in
the three groups. Synovial hypertrophy,
synovial inflammation, and erosive disease
were present to a similar degree in the
MRL-Ipr/lpr mice regardless of NOS2
genotype (86).
Infiltrates of lymphocytes and
perivascular collection oflymphocytes occur
in the kidneys ofall /pr mice regardless of
genetic background (64,87); true medium-
to-large vessel vasculitis is found, however,
only in MRL-lpr/iprmice (87-89). Mono-
nuclear cell infiltrates were present in the
kidneys ofall mice in this study. However,
in contrast to glomerulonephritis and arth-
ritis, there was a significant difference in the
presence and severity ofmedium-to-large
vessel vasculitis, depending on NOS2 geno-
type. Indeed, 4 of6 (+/+) mice had prom-
inentvasculitis ofmedium-to-largevessels in
the kidney, whereas only 1 of9 ofthe (+/-)
mice and 0 of9 of(-/-) mice had medium-
to-large vessel vasculitis. The incidence of
vasculitis in the (+/+) mice was similar to
that in 20-week-old female MRL-lpr/lpr
mice (80%). The difference in the occur-
rence ofvasculitis between the (+/+) mice
and the (-/-) mice was statistically signifi-
cant. Pathologic examination ofthe brain,
liver, lymph nodes, spleen, and lung re-
vealed similar mild lymphocytic infiltration
in all threegroups (86).
MRL-lpr/lpr mice are notable for
autoantibody production (64,87). We
therefore determined ifMRL-lpr/lpr mice
of various NOS2 genotypes displayed
qualitative or quantitative differences in
autoantibody production. Serum levels of
antibodies to single-strand or double-
strand DNA did not differ in the various
mice. These results are comparable to the
lack of effect of NMMA treatment on
anti-DNA production we noted before in
MRL-lpr/lpr mice (66). However, there
was a shift in the isotype ofanti-DNA
antibodies produced. The IgGl/IgG3 ratio
ofanti-DNA antibodies was higher in the
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(-/-) mice. In contrast to anti-DNA
production, rheumatoid factor (RF)
production differed among the MRL-
lpr/Ilpr mice ofvarious NOS2 genotypes.
The (-/-) mice produced significantly less
IgG RF than did (+/+) mice. IgM RF levels
were also lower in the (-/-) mice, but levels
were not significantly different from those
in (+/+) mice. IgG3 RF activity [known to
be associated with small-vessel but not
medium-vessel vasculitis in MRL-lpr/lpr
mice (90)], was similar in the three groups
of mice. Total serum IgG and IgM were
similar in the three groups, as were serum
levels ofanti-Sm and anti-La antibodies.
The different antibody levels in NOS2-dis-
rupted mice may highlight the fact that
small amounts of NO can modulate B-cell
function by modifying bcl-2 levels and
apoptosis (91).
The mechanism(s) for the contrasting
effects on renal and synovial diseases ofa
genetically disrupted NOS2 as opposed to
pharmacological inhibition ofNOS activ-
itywith NMMA is not clear (Table 1). It is
unlikely that there were compensatory
increases in NOS1 or NOS3 in the (-/-)
mice, since we noted very low total body
NO production in the (-/-) mice.
NMMA is an isoform-nonspecific NOS
Table 1. Nitric oxide and autoimmune disease in MRL-/pr/lprmice.a
NO production NOS2 expression Glomerulo-
Mouse in vivob in vivoc nephritisd Arthritisd Vasculitisd
Normal (BALB/c) oe 0 O 0 0
MRL-Ipr/lpr 4+ 4+ 3+ 3+ 3+
MRL-/pr/lprtreated 0 NDf 0 0 0
with NMMA
MRL-/pr/lpr-NOS2 (-I-) 0 0 3+ 3+ 0
aSummarized from Weinberg et al.(66) and Gilkeson et al. (86). bDetermined by urinary nitrate/nitrite excretion or
plasma nitrate/nitrite. cDetermined by analyses of peritoneal macrophages, spleen, liver, and kidney tissues for
mRNA by Northern blot analysis and protein by immunoblot. dDetermined by histologic analyses of tissues.
eDegree of positivity, with 0 being none and 4+ being the maximum.'Not determined.
inhibitor, blocking all three isoforms ofthe
NOS enzymes (92). Inhibiting all NOS
isoforms (and hence potentially all NO
production) with NMMA may be more
effective in disease prevention than geneti-
cally disrupting only NOS2. Alternative
inflammatory pathways may not be active
when NO production is acutely blocked
by NMMA; however, these pathways
might become active over time when
NOS2 is genetically disrupted and absent
the entire life ofthe animal.
Conclusions
Thus, MRL-/pr/lpr mice spontaneously
overexpress NOS2 and overproduce NO
in parallel with the development
of autoimmunity and inflammation.
Inhibiting 'NO production in vivo by oral
administration ofNMMA from 10 to 20
weeks ofage prevents development ofglo-
merulonephritis, arthritis, and vasculitis.
This indicates that 'NO is important in the
pathogenesis ofglomerulonephritis, arthri-
tis, and vasculitis in these mice. However,
in MRL-/pr/lpr mice with genetically dis-
rupted NOS2, arthritis and glomeru-
lonephritis are unaltered, whereas vasculitis
is reduced. These studies highlight the
heterogeneity and complexity ofthe roles
of NOS2 and 'NO in inflammation in
MRL-Ipr/Iprmice.
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